| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(10 months ago) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(9 months ago) | |
| US7320969 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jan, 2024
(2 months ago) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(4 years from now) | |
Seasonique is owned by Teva Branded Pharm.
Seasonique contains Ethinyl Estradiol; Levonorgestrel.
Seasonique has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Seasonique are:
- US7615545
- US7858605
- US7320969
Seasonique was authorised for market use on 25 May, 2006.
Seasonique is available in tablet;oral dosage forms.
Seasonique can be used as prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception, prevention of pregnancy.
The generics of Seasonique are possible to be released after 05 December, 2028.
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 25 May, 2006
Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
SEASONIQUE family patents
